Dai W Q, Gu X F, Yu Y G
Department of Pediatric Endocrinology and Genetics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Zhonghua Er Ke Za Zhi. 2020 Jun 2;58(6):461-467. doi: 10.3760/cma.j.cn112140-20200217-00096.
To summarize the clinical manifestation and genetic characteristics of Chinese patients with achondroplasia (ACH) which is caused by pathogenic variants fibroblast growth factor receptor 3 (FGFR3) gene and establish the reference value of height centiles and height for age growth curve of patients for a more practical, simple and useful growth evaluation tool in China. Through a nationwide cross-sectional survey in China from July 2019 to January 2020 designed by Department of Pediatric Endocrinology and Genetics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 210 subjects (110 boys, 100 girls), who harbored the pathogenic variant of FGFR3 gene and were diagnosed with achondroplasia, were recruited. The clinical and genetic data of enrolled subjects were collected and analyzed to explore the clinical genetic characteristics of Chinese ACH patients. Furthermore, according to the data of height (body length under 2 years old) of boy and girl subjects aged 0-12 years, centiles and height for age growth curve of achondroplasia were calculated and established by LMS method respectively. The characteristic clinical manifestations of 210 Chinese patients (0-14 years old) were disproportionate short stature (206/210, 98.1%), macrocephaly and characteristic facial features (205/210, 97.6%), trident configuration of the hands (191/210, 90.9%), limbs deformity (156/210, 74.3%), together with normal intelligence. Up to 81.9% (172/210) of patients have different complications, and the kyphosis (121/210, 57.6%) and narrow thoracic (79/210, 37.6%) are common complications. Besides, up to 98.6% (207/210) of patients harbored hotspot variants of FGFR3 gene which cause G380R amino acid substitutions. It is notable that the growth pattern of boy and girl patients (0-12 years old) is obviously different from the normal children (9.849, 9.596, 0.01) respectively. The height different between ACH patients and normal children gradually widened with age. The average height of the boy (49.2 cm) and girl patients(48.4 cm) of achondroplasia at birth was -1.22 and -2 , however, at the age of twelve, the average height of the boy(113.7 cm) and girl patients(112.4 cm) of achondroplasia was -5.23 and -6.15 compared to currently standard reference height for age growth curve of normal children in China, respectively. The results of our study demonstrated that in China disproportionate short stature, macrocephaly and characteristic facial features were typical manifestations of ACH patients, and that up to 98.6% of patients harbored hotspot variants of FGFR3 gene. In addition, the reference value of height centiles and height for age growth curve of ACH patients we establish will be a valuable tool for evaluating the growth pattern, monitoring factors affecting growth, estimating ultimate height, and assessing the curative effect of growth-promoting treatments in Chinese patients with achondroplasia.
总结由成纤维细胞生长因子受体3(FGFR3)基因致病性变异引起的中国软骨发育不全(ACH)患者的临床表现和遗传特征,并建立患者身高百分位数和年龄别身高生长曲线的参考值,以便在中国提供一种更实用、简单且有效的生长评估工具。通过上海交通大学医学院附属新华医院小儿内分泌与遗传学科于2019年7月至2020年1月在中国开展的一项全国性横断面调查,招募了210名携带FGFR3基因致病性变异且被诊断为软骨发育不全的受试者(110名男孩,100名女孩)。收集并分析纳入受试者的临床和遗传数据,以探索中国ACH患者的临床遗传特征。此外,根据0至12岁男孩和女孩受试者的身高(2岁以下为身长)数据,分别采用LMS法计算并建立软骨发育不全患者的身高百分位数和年龄别身高生长曲线。210例中国患者(0至14岁)的特征性临床表现为身材不成比例矮小(206/210,98.1%)、巨头畸形和特征性面部特征(205/210,97.6%)、三叉手畸形(191/210,90.9%)、肢体畸形(156/210,74.3%),且智力正常。高达81.9%(172/210)的患者有不同并发症,脊柱后凸(121/210,57.6%)和胸廓狭窄(79/210,37.6%)是常见并发症。此外,高达98.6%(207/210)的患者携带导致G380R氨基酸替代的FGFR3基因热点变异。值得注意的是,0至12岁男孩和女孩患者的生长模式与正常儿童明显不同(分别为9.849、9.596、0.01)。ACH患者与正常儿童的身高差异随年龄逐渐增大。软骨发育不全男孩患者(49.2厘米)和女孩患者(48.4厘米)出生时的平均身高分别比中国正常儿童当前年龄别身高生长曲线的标准参考身高低-1.22和-2,然而,在12岁时,软骨发育不全男孩患者(113.7厘米)和女孩患者(112.4厘米)的平均身高分别比中国正常儿童当前年龄别身高生长曲线的标准参考身高低-5.23和-6.15。我们的研究结果表明,在中国,身材不成比例矮小、巨头畸形和特征性面部特征是ACH患者的典型表现,且高达98.6%的患者携带FGFR3基因热点变异。此外,我们建立的ACH患者身高百分位数和年龄别身高生长曲线参考值将成为评估中国软骨发育不全患者生长模式、监测影响生长的因素、估计最终身高以及评估促生长治疗疗效的有价值工具。